Key Highlights

  • HCA Healthcare (NYSE:HCA) reports third quarter 2026 results before the market open on Tuesday, October 27, 2026, with consensus earnings of USD 6.63 per share.
  • Management narrowed and lowered 2026 diluted earnings guidance to USD 28.70 to USD 30.50 per share from USD 29.10 to USD 31.50 on Tuesday, July 14, 2026, citing a shift towards uninsured patients.
  • Second quarter revenue of USD 20.23 billion rose 8.7%, and same-facility admissions rose 2.5%, so HCA Healthcare (NYSE:HCA) is judged on volume against payer mix.
  • The company estimated that coverage losses on the insurance exchanges cut second quarter pre-tax income by about USD 400 million, offset by a similar gain from Medicaid supplemental payments.

HCA Healthcare (NYSE:HCA): a lowered range sets the starting point

HCA Healthcare (NYSE:HCA), the largest for-profit hospital operator in the United States, reports third quarter 2026 results before the open on Tuesday, October 27, 2026. Consensus earnings are USD 6.63 per share. On Friday, July 24, 2026 it reported second quarter revenue of USD 20.23 billion, up 8.7%, adjusted earnings of USD 7.59 per share, up 11.0%, and adjusted EBITDA of USD 4.03 billion, a margin of 19.9%. Full-year guidance, set on Tuesday, July 14, 2026, is revenue of USD 77.0 billion to USD 79.5 billion, adjusted EBITDA of USD 15.4 billion to USD 16.1 billion and capital spending of USD 5.0 billion to USD 5.5 billion. Results cannot be known in advance.

Why Payer Mix Matters More Than Volume

A hospital earns far more from a patient with private insurance than from an uninsured one, so the mix of payers can move profit even when admissions grow. HCA Healthcare (NYSE:HCA) reported that patients who lost coverage on the health insurance exchanges raised its uninsured volume, and it estimated the effect at about USD 400 million of pre-tax income in the second quarter, USD 75 million more than its first quarter estimate. A gain of about USD 400 million from Medicaid supplemental payment programmes, mainly in Florida, offset it. Surgical volume was also lower. The third quarter shows whether these two forces continue to cancel, because supplemental payments depend on state programmes and uninsured volume depends on coverage rules.

Risks and What to Watch

The positive case is earnings above USD 6.63 per share, same-facility admissions growth above 2.5% and a narrowed full-year range that holds the USD 28.70 lower bound. That would suggest the July reduction was cautious and could relieve pressure on the shares. The negative case is a further rise in uninsured volume, a second cut to the range or supplemental payments that fall short of the offset. Commentary on the exchange coverage losses and on surgical volume would be scrutinised closely. No options-implied move was found. The Federal Reserve decides on Wednesday, October 28, 2026 after the September rate rise, which raises financing costs for a company with heavy capital spending.

Where Things Stand

The answer is that HCA Healthcare (NYSE:HCA) needs to show that uninsured volume has stabilised and that the lowered range of USD 28.70 to USD 30.50 per share is safe. Consensus of USD 6.63 is the bar for the quarter, but the outlook for 2027 payer mix will drive the shares. The next catalysts are the HCA Healthcare (NYSE:HCA) release before the open on Tuesday, October 27, 2026, its call that day, the Federal Reserve decision on Wednesday, October 28, 2026 and later hospital sector results. Estimates can change, and this is not investment advice.